News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2012

Epigenomics AG to Provide an Update on the Septin9 Program During a Corporate Workshop on Colorectal Cancer Screening at the Association of Molecular Pathology (AMP) 2012 Annual Meeting

Partners Quest Diagnostics and ARUP Laboratories to discuss experiences with laboratory developed test versions using the methylated Septin9 DNA biomarker 22.10.2012 | Press_release_Epigenomics_AG_AMP_Workshop Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today announced that it will host a corporate workshop at the Association of Molecular […]

Read more

Epigenomics AG Announces Changes to Management Team

25.09.2012 | 120925_Press_Release_Epigenomics_AG_Changes_to_Management_Team Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that Dr. Thomas Taapken, currently Chief Financial Officer at Epigenomics, has been appointed by the Board of Directors to serve as acting Chief Executive Officer in addition to his responsibilities as […]

Read more

Ad hoc: Epigenomics AG announces changes in its Executive Management Board

PDF 85 KB   Berlin, Germany, September 25, 2012 – The Supervisory Board of Epigenomics AG (ISIN: DE000A1K0516) and its current CEO Geert Walter Nygaard today agreed that Mr. Nygaard will leave the Executive Management Board of the company effective 30 September 2012. The current CFO, Dr. Thomas Taapken, thereby becomes the sole Executive Board […]

Read more

Epigenomics AG Announces First Half 2012 Financial Results and Reports Operational Highlights

08.08.2012 | Press_release_Epigenomics_H1_results Berlin, Germany, and Seattle, WA, U.S.A., – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced its financial results for the first half and second quarter ending June 30, 2012.

Read more

Epigenomics welcomes reimbursement of the Septin9 blood based colorectal cancer test by Swiss Life in France

05.07.2012 | 07052012Epigenomics_Swiss_Life_announcement_July_05_2012 Berlin, Germany, and Seattle, WA, U.S.A., July 05, 2012 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that Swiss Life, France’s third largest private health insurance company, with nearly two million policyholders, will provide the Septin9 blood based test for the early detection of colorectal […]

Read more

Epigenomics AG announces non-exclusive licensing agreement for Septin9 with Companion Dx Reference Lab

19.06.2012 | Press_release_Epigenomics_AG_CompanionDx_deal Berlin, Germany, and Seattle, WA, U.S.A., June 19, 2012 – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that it signed a non-exclusive licensing agreement for its proprietary DNA methylation biomarker Septin9 with Companion Dx Reference Lab (“Companion Dx”), an emerging leader in pharmacogenomic testing and […]

Read more